Cargando…

Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer

BACKGROUND: We present the 2-year results of a randomised trial comparing 4- versus 12-weekly bone-targeting agents (BTAs) in patients with bone metastases from breast or castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS: Patients with bone metastases from breast or CRPC, who were go...

Descripción completa

Detalles Bibliográficos
Autores principales: Clemons, Mark, Liu, Michelle, Stober, Carol, Pond, Gregory, Jemaan Alzahrani, Mashari, Ong, Michael, Ernst, Scott, Booth, Christopher, Mates, Mihaela, Abraham Joy, Anil, Aseyev, Olexiy, Blanchette, Phillip, Vandermeer, Lisa, Tu, Megan, Thavorn, Kednapa, Fergusson, Dean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449269/
https://www.ncbi.nlm.nih.gov/pubmed/34567960
http://dx.doi.org/10.1016/j.jbo.2021.100388
_version_ 1784569396797112320
author Clemons, Mark
Liu, Michelle
Stober, Carol
Pond, Gregory
Jemaan Alzahrani, Mashari
Ong, Michael
Ernst, Scott
Booth, Christopher
Mates, Mihaela
Abraham Joy, Anil
Aseyev, Olexiy
Blanchette, Phillip
Vandermeer, Lisa
Tu, Megan
Thavorn, Kednapa
Fergusson, Dean
author_facet Clemons, Mark
Liu, Michelle
Stober, Carol
Pond, Gregory
Jemaan Alzahrani, Mashari
Ong, Michael
Ernst, Scott
Booth, Christopher
Mates, Mihaela
Abraham Joy, Anil
Aseyev, Olexiy
Blanchette, Phillip
Vandermeer, Lisa
Tu, Megan
Thavorn, Kednapa
Fergusson, Dean
author_sort Clemons, Mark
collection PubMed
description BACKGROUND: We present the 2-year results of a randomised trial comparing 4- versus 12-weekly bone-targeting agents (BTAs) in patients with bone metastases from breast or castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS: Patients with bone metastases from breast or CRPC, who were going to start or were already receiving BTAs, were randomised to 4- or 12-weekly BTA treatment for 2 years. The endpoints were: symptomatic skeletal events (SSE) rates, time to SSEs, toxicity and cost-effectiveness. RESULTS: Of 263 patients (160 breast cancer, 103 CRPC), 133 (50.6%) and 130 (49.4%) were randomised to the 4- and 12-weekly groups, respectively. BTAs included denosumab (56.3%), zoledronate (24.0%) and pamidronate (19.8%). After 2 years, the cumulative incidence rate (95% CI) of SSEs was 32.7% (24.6% to 41.1%) and 28.1% (20.3% to 36.4%) for the 4- and 12-weekly intervention groups respectively. The hazard ratio for time to first SSE was 0.96 (95% CI = 0.63 to 1.47). However, in a post hoc analysis, those patients who had an on-study SSE, there was a small non-statistical increased risk of subsequent SSEs among patients on the 12-weekly dosing arm (HR = 1.14; 95% CI – 0.90–1.44). BTA-related toxicity rates were similar between study arms. A cost-utility analysis showed that 12-weekly BTA is cost-effective from a public payer’s perspective. CONCLUSION: These results in addition to those previously reported for de-escalating zoledronate, would support that de-escalation of commonly used BTAs is a reasonable and economically valid treatment option. While not statistically significant, the increase in subsequent SSEs in the 12-weekly arm requires further exploration.
format Online
Article
Text
id pubmed-8449269
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84492692021-09-24 Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer Clemons, Mark Liu, Michelle Stober, Carol Pond, Gregory Jemaan Alzahrani, Mashari Ong, Michael Ernst, Scott Booth, Christopher Mates, Mihaela Abraham Joy, Anil Aseyev, Olexiy Blanchette, Phillip Vandermeer, Lisa Tu, Megan Thavorn, Kednapa Fergusson, Dean J Bone Oncol Research Paper BACKGROUND: We present the 2-year results of a randomised trial comparing 4- versus 12-weekly bone-targeting agents (BTAs) in patients with bone metastases from breast or castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS: Patients with bone metastases from breast or CRPC, who were going to start or were already receiving BTAs, were randomised to 4- or 12-weekly BTA treatment for 2 years. The endpoints were: symptomatic skeletal events (SSE) rates, time to SSEs, toxicity and cost-effectiveness. RESULTS: Of 263 patients (160 breast cancer, 103 CRPC), 133 (50.6%) and 130 (49.4%) were randomised to the 4- and 12-weekly groups, respectively. BTAs included denosumab (56.3%), zoledronate (24.0%) and pamidronate (19.8%). After 2 years, the cumulative incidence rate (95% CI) of SSEs was 32.7% (24.6% to 41.1%) and 28.1% (20.3% to 36.4%) for the 4- and 12-weekly intervention groups respectively. The hazard ratio for time to first SSE was 0.96 (95% CI = 0.63 to 1.47). However, in a post hoc analysis, those patients who had an on-study SSE, there was a small non-statistical increased risk of subsequent SSEs among patients on the 12-weekly dosing arm (HR = 1.14; 95% CI – 0.90–1.44). BTA-related toxicity rates were similar between study arms. A cost-utility analysis showed that 12-weekly BTA is cost-effective from a public payer’s perspective. CONCLUSION: These results in addition to those previously reported for de-escalating zoledronate, would support that de-escalation of commonly used BTAs is a reasonable and economically valid treatment option. While not statistically significant, the increase in subsequent SSEs in the 12-weekly arm requires further exploration. Elsevier 2021-09-02 /pmc/articles/PMC8449269/ /pubmed/34567960 http://dx.doi.org/10.1016/j.jbo.2021.100388 Text en © 2021 Published by Elsevier GmbH. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Clemons, Mark
Liu, Michelle
Stober, Carol
Pond, Gregory
Jemaan Alzahrani, Mashari
Ong, Michael
Ernst, Scott
Booth, Christopher
Mates, Mihaela
Abraham Joy, Anil
Aseyev, Olexiy
Blanchette, Phillip
Vandermeer, Lisa
Tu, Megan
Thavorn, Kednapa
Fergusson, Dean
Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
title Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
title_full Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
title_fullStr Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
title_full_unstemmed Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
title_short Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
title_sort two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449269/
https://www.ncbi.nlm.nih.gov/pubmed/34567960
http://dx.doi.org/10.1016/j.jbo.2021.100388
work_keys_str_mv AT clemonsmark twoyearresultsofarandomisedtrialcomparing4versus12weeklybonetargetedagentuseinpatientswithbonemetastasesfrombreastorcastrationresistantprostatecancer
AT liumichelle twoyearresultsofarandomisedtrialcomparing4versus12weeklybonetargetedagentuseinpatientswithbonemetastasesfrombreastorcastrationresistantprostatecancer
AT stobercarol twoyearresultsofarandomisedtrialcomparing4versus12weeklybonetargetedagentuseinpatientswithbonemetastasesfrombreastorcastrationresistantprostatecancer
AT pondgregory twoyearresultsofarandomisedtrialcomparing4versus12weeklybonetargetedagentuseinpatientswithbonemetastasesfrombreastorcastrationresistantprostatecancer
AT jemaanalzahranimashari twoyearresultsofarandomisedtrialcomparing4versus12weeklybonetargetedagentuseinpatientswithbonemetastasesfrombreastorcastrationresistantprostatecancer
AT ongmichael twoyearresultsofarandomisedtrialcomparing4versus12weeklybonetargetedagentuseinpatientswithbonemetastasesfrombreastorcastrationresistantprostatecancer
AT ernstscott twoyearresultsofarandomisedtrialcomparing4versus12weeklybonetargetedagentuseinpatientswithbonemetastasesfrombreastorcastrationresistantprostatecancer
AT boothchristopher twoyearresultsofarandomisedtrialcomparing4versus12weeklybonetargetedagentuseinpatientswithbonemetastasesfrombreastorcastrationresistantprostatecancer
AT matesmihaela twoyearresultsofarandomisedtrialcomparing4versus12weeklybonetargetedagentuseinpatientswithbonemetastasesfrombreastorcastrationresistantprostatecancer
AT abrahamjoyanil twoyearresultsofarandomisedtrialcomparing4versus12weeklybonetargetedagentuseinpatientswithbonemetastasesfrombreastorcastrationresistantprostatecancer
AT aseyevolexiy twoyearresultsofarandomisedtrialcomparing4versus12weeklybonetargetedagentuseinpatientswithbonemetastasesfrombreastorcastrationresistantprostatecancer
AT blanchettephillip twoyearresultsofarandomisedtrialcomparing4versus12weeklybonetargetedagentuseinpatientswithbonemetastasesfrombreastorcastrationresistantprostatecancer
AT vandermeerlisa twoyearresultsofarandomisedtrialcomparing4versus12weeklybonetargetedagentuseinpatientswithbonemetastasesfrombreastorcastrationresistantprostatecancer
AT tumegan twoyearresultsofarandomisedtrialcomparing4versus12weeklybonetargetedagentuseinpatientswithbonemetastasesfrombreastorcastrationresistantprostatecancer
AT thavornkednapa twoyearresultsofarandomisedtrialcomparing4versus12weeklybonetargetedagentuseinpatientswithbonemetastasesfrombreastorcastrationresistantprostatecancer
AT fergussondean twoyearresultsofarandomisedtrialcomparing4versus12weeklybonetargetedagentuseinpatientswithbonemetastasesfrombreastorcastrationresistantprostatecancer
AT twoyearresultsofarandomisedtrialcomparing4versus12weeklybonetargetedagentuseinpatientswithbonemetastasesfrombreastorcastrationresistantprostatecancer